SLC5A2 and diabetic kidney disease: SGLT2 inhibitors have been clearly shown in multiple trials to improve renal outcomes in patients with CKD or DKD, improve glomerular hemodynamic function, and significantly decrease the risk of proteinuria and renal failure.